Staar Surgical (STAA) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Staar Surgical reported a revenue of $44.32 million for the quarter ended June 2025, marking a year-over-year decline of 55.2% and an EPS of -$0.07 compared to $0.33 a year ago, indicating significant financial challenges [1] - The revenue exceeded the Zacks Consensus Estimate of $41.56 million by 6.63%, while the EPS surprise was 87.5% against a consensus estimate of -$0.56, suggesting better-than-expected performance in terms of earnings [1] Revenue Performance - Net Geographic Sales in the United States were $5.64 million, slightly below the average estimate of $6.46 million, reflecting a year-over-year increase of 4.4% [4] - Net Geographic Sales from Other International markets totaled $18.18 million, significantly lower than the average estimate of $24.03 million, showing a year-over-year decline of 10.6% [4] - Sales in Japan reached $10.92 million, surpassing the average estimate of $10.08 million with a year-over-year increase of 10.4% [4] - In China, sales were reported at $5.3 million, a dramatic drop from the average estimate of $0.96 million, representing a year-over-year decline of 91.6% [4] Stock Performance - Staar Surgical's shares have returned +59.8% over the past month, significantly outperforming the Zacks S&P 500 composite, which saw a change of +0.5% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]